CAR T-Cell trial for rare lymphoma halted after just one patient
Disease control
Terminated
This study tested a CAR T-cell therapy called axicabtagene ciloleucel in people with a rare type of lymphoma (PMBCL) that came back or didn't respond to initial treatment. The goal was to see if it could make the cancer disappear. However, the study was stopped early and only enr…
Phase: PHASE2 • Sponsor: Universität Münster • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC